Therapeutic agent for psoriasis
Inventors
Tamai, Katsuto • SHIMBO, Takashi • Yamazaki, Takehiko
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12428458-B2
Publication Date
2025-09-30
Expiration Date
Abstract
The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.
Core Innovation
The invention relates to HMGB1 fragment peptides for pharmaceutical prevention and/or treatment of psoriasis. The peptides are defined by an amino-acid sequence including SEQ ID NO: 1, as well as peptides consisting of SEQ ID NO: 1 with one or two additional amino acids. The approach is directed to modulating psoriasis in a patient by administering an effective amount of the HMGB1 fragment peptide.
The problem addressed is the presence of psoriasis symptoms, including erythema, scaling/desquamation, and thickening and infiltration, together with psoriasis-associated inflammatory cytokine expression. In the provided animal model, the HMGB1 fragment peptide administration is reported to suppress key plaque-psoriasis symptoms and reduce expression of inflammatory cytokines including IL-6, IL-17F, and IL-22, and additionally IL-1β and IL-17A in an example.
Claims Coverage
The document provides two independent claims describing methods: one for treating psoriasis and one for suppressing selected skin symptoms in a patient with psoriasis. Across these independent claims, the inventive coverage centers on administering an effective amount of an HMGB1 fragment peptide defined by SEQ ID NO: 1 (or SEQ ID NO: 1 with one or two additional amino acids) with an effect on specified psoriasis-associated skin features.
Treating psoriasis with an HMGB1 fragment peptide
A method of treating psoriasis by administering to a patient with psoriasis an effective amount of a peptide selected from a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one or two additional amino acids and having an effect of suppressing erythema, thickening, and scaling of the skin.
Suppressing psoriasis skin symptoms with an HMGB1 fragment peptide
A method of suppressing a skin symptom selected from erythema, thickening, scaling and desquamation in a patient with psoriasis by administering to the patient an effective amount of a peptide selected from a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one or two additional amino acids and having an effect of suppressing erythema, thickening, and scaling of the skin.
Claim coverage focuses on two related therapeutic method framings using an HMGB1 fragment peptide defined by SEQ ID NO: 1, including variants with one or two additional amino acids, where the peptide is administered in an effective amount to treat psoriasis or suppress specified skin symptoms, including suppression of erythema, thickening, and scaling.
Stated Advantages
Suppresses erythema, thickening, and scaling of the skin in a subject with psoriasis.
Suppresses a skin symptom selected from erythema, thickening, scaling and desquamation in a patient with psoriasis.
Reduces psoriasis-associated inflammatory cytokine expression, including IL-6, IL-17F, IL-22, and additionally IL-1β and IL-17A as reported in examples.
Documented Applications
Pharmaceutical prevention and/or treatment of psoriasis using an HMGB1 fragment peptide with an amino-acid sequence including SEQ ID NO: 1.
Suppression of skin symptoms of psoriasis, including erythema, thickening, scaling, and desquamation, by administering an effective amount of the HMGB1 fragment peptide.
Interested in licensing this patent?